

AUSTRALIAN PRODUCT INFORMATION

INCRUSE ELLIPTA (umeclidinium bromide) powder for inhalation

1 NAME OF THE MEDICINE

Umeclidinium (as bromide).

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Moulded plastic device containing one foil strip of either 7 or 30 regularly distributed blisters, each containing a white powder. Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 micrograms of umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide).

Umeclidinium bromide is slightly soluble in water and slightly soluble in methanol, ethanol, acetonitrile and propan-1-ol.

List of excipients with known effect

Lactose monohydrate (which contains milk protein).

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Powder for inhalation.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

INCRUSE ELLIPTA is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

4.2 DOSE AND METHOD OF ADMINISTRATION

INCRUSE ELLIPTA is for oral inhalation use only.

Adults

INCRUSE ELLIPTA (umeclidinium 62.5 micrograms) should be taken as one inhalation once daily by the orally inhaled route.

INCRUSE ELLIPTA should be taken at the same time everyday.

Do not use INCRUSE ELLIPTA more than once every 24 hours.

Dosing Considerations

INCRUSE ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing a long-acting muscarinic antagonist, as an overdose may result.

When beginning treatment with INCRUSE ELLIPTA, patients who have been taking inhaled, short-acting muscarinic antagonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.

Patients should be made aware that for optimum benefit, INCRUSE ELLIPTA must be used regularly, even when asymptomatic.

Special populations

Paediatric populations

This product should not be used in children.

Elderly population

No dosage adjustment is required in patients over 65 years (see Pharmacokinetics – Special Patient Populations).

Renal impairment

No dosage adjustment is required in patients with renal impairment (See Section 5.2 PHARMOKINETIC PROPERTIES, Special Patient Populations).

Hepatic impairment

No dosage adjustment is required in patients with mild or moderate hepatic impairment. INCRUSE ELLIPTA has not been studied in patients with severe hepatic impairment (See Section 5.2 PHARMOKINETIC PROPERTIES, Special Patient Populations).

4.3 CONTRAINDICATIONS

INCRUSE ELLIPTA is contraindicated in patients with severe milk-protein allergy or who have demonstrated hypersensitivity to either umeclidinium or any of the excipients.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Asthma

The use of INCRUSE ELLIPTA has not been studied in patients with asthma, and is not recommended in this patient population.

Deterioration of Disease and Acute Episodes

INCRUSE ELLIPTA is intended for the long-term maintenance treatment of COPD.

INCRUSE ELLIPTA has not been studied in subjects with acutely deteriorating COPD. The initiation of INCRUSE ELLIPTA in this setting is not appropriate.

INCRUSE ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose.

When prescribing INCRUSE ELLIPTA, it is recommended the physician advise the patient to have an inhaled, short-acting beta₂-agonist for treatment of acute symptoms available at all times.

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If INCRUSE ELLIPTA no longer controls symptoms of bronchoconstriction, the patient's inhaled, short-acting beta₂-agonist becomes less effective or the patient needs more inhalation of a short-acting beta₂-agonist than usual to relieve symptoms, these may be markers of deterioration of disease control. In this setting a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once by a physician. Increasing the daily dose of INCRUSE ELLIPTA beyond the recommended dose is not appropriate in this situation.

Exacerbations may occur during treatment with INCRUSE ELLIPTA. Patients should be advised to continue treatment and seek medical advice if COPD symptoms remain uncontrolled or worsen after initiation of therapy with INCRUSE ELLIPTA.

Paradoxical Bronchospasm

As with other inhalation therapies, administration of INCRUSE ELLIPTA may produce paradoxical bronchospasm that may be life threatening. Treatment with INCRUSE ELLIPTA should be discontinued if paradoxical bronchospasm occurs and alternative therapy instituted if necessary.

Cardiovascular Effects

Cardiovascular effects, such as cardiac arrhythmias e.g. atrial fibrillation and tachycardia, may be seen after the administration of muscarinic receptor antagonists, including INCRUSE ELLIPTA. Therefore, INCRUSE ELLIPTA should be used with caution in patients with severe cardiovascular disorders, particularly cardiac arrhythmias.

Antimuscarinic Activity

Consistent with its antimuscarinic activity, INCRUSE ELLIPTA should be used with caution in patients with narrow-angle glaucoma or urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g. eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema). Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develop.

Excipients

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take INCRUSE ELLIPTA.

Use in the elderly

There are no special precautions for use in the elderly.

Paediatric use

This product should not be used in children.

Effects on laboratory tests

Interactions with laboratory tests have not been established.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Clinically significant drug interactions mediated by umeclidinium at clinical doses are considered unlikely due to the low plasma concentrations achieved after inhaled dosing.

Interaction with P-glycoprotein inhibitors

Umeclidinium is a substrate of P-glycoprotein (P-gp) transporter. The effect of the P-gp transporter inhibitor verapamil (240 mg once daily) on the steady-state pharmacokinetics of umeclidinium was assessed in healthy volunteers. No effect of verapamil was observed on umeclidinium C_{max}. An approximately 1.4 fold increase in umeclidinium AUC was observed.

Based on the magnitude of these changes, no clinically relevant drug interaction is expected when umeclidinium is co-administered with P gp inhibitors.

Interaction with CYP2D6 inhibitors

Umeclidinium is a substrate of CYP2D6. The effect of a CYP2D6 poor metaboliser genotype on the steady-state pharmacokinetics of umeclidinium was assessed in healthy volunteers (CYP2D6 normal metabolisers and CYP2D6 poor metabolisers). No clinically meaningful difference in systemic exposure to umeclidinium (500 micrograms) was observed following repeat daily inhaled dosing to normal and CYP2D6 poor metaboliser subjects.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no data on the effects of INCRUSE ELLIPTA on human fertility. Studies in rats showed no effects of umeclidinium on male or female fertility at doses producing very large multiples of the systemic exposure in patients.

Use in pregnancy

(Pregnancy Category B1):

There is a limited amount of data from the use of INCRUSE ELLIPTA in pregnant women. Embryo-foetal development was unaffected by umeclidinium in rats treated at up to 278 micrograms/kg/day by inhalation (estimated to yield 50 times the plasma AUC in patients at the maximum recommended human dose of 62.5 micrograms per day) and in rabbits treated at up to 306 micrograms/kg/day by inhalation or up to 180 micrograms/kg/day subcutaneously (yielding 35 and ~200 times the plasma AUC in patients).

INCRUSE ELLIPTA should only be used during pregnancy if the expected benefit to the mother justifies the potential risk to the foetus.

Use in lactation

It is unknown whether umeclidinium is excreted in human milk. A risk to breastfed newborns/infants cannot be excluded.

A decision must be made whether to discontinue breastfeeding or to discontinue INCRUSE ELLIPTA therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

There have been no studies to investigate the effect of INCRUSE ELLIPTA on the ability to perform tasks that require judgement, motor or cognitive skills. There have been no adverse effects associated with INCRUSE ELLIPTA that would affect the ability to perform tasks that require judgement, motor or cognitive skills.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Umeclidinium as monotherapy

Clinical trial data

Table 1 shows all adverse events that occurred with a frequency of greater than 1% in either of the groups receiving INCRUSE ELLIPTA in the four 24-week well-controlled studies where the rates in either of the groups receiving INCRUSE ELLIPTA exceeded placebo by greater than 1%.

Table 1 Adverse Events with >1% Incidence and greater than Placebo by 1% with INCRUSE ELLIPTA in Subjects with COPD

Preferred Term	Number (%) of Subjects		
	Placebo (N=623)	UMEC 62.5 (N=487)	UMEC 125 (N=698)
Respiratory, Thoracic and Mediastinal Disorders			
Cough	24 (4)	16 (3)	34 (5)
Infections and Infestations			
Upper respiratory tract infection	21 (3)	23 (5)	25 (4)
Viral upper respiratory tract infection	1 (<1)	7 (1)	1 (<1)
Vascular Disorders			
Hypertension	10 (2)	10 (2)	19 (3)
Contusion	1 (<1)	7 (1)	4 (<1)
Immune System Disorders			
Arthralgia	9 (1)	12 (2)	11 (2)

52 week study

In a long-term safety study, 336 subjects (n=227 umeclidinium 125 micrograms, n=109 placebo) were treated for up to 52 weeks with umeclidinium 125 micrograms or placebo. The demographic and baseline characteristics of the long-term safety study were similar to those of the efficacy studies. In addition to the adverse events listed in Table 1, the adverse events reported in subjects receiving umeclidinium 125 micrograms with a frequency of greater than 1% and exceeding the rate in subjects receiving placebo by greater than 1% in this study were: nasopharyngitis (umeclidinium 125 micrograms 9%, placebo 5%), supraventricular extrasystoles (umeclidinium 125 micrograms 3%, placebo <1%), supraventricular

tachycardia (umeclidinium 125 micrograms 3%, placebo <1%), rhythm idioventricular (umeclidinium 125 micrograms 2%, placebo 0%), and urinary tract infection (umeclidinium 125 micrograms 2%, placebo 0%).

The safety profile of INCRUSE ELLIPTA was evaluated from 1663 patients with COPD who received doses of 62.5 micrograms or greater for up to one year. This includes 576 patients who received the recommended dose of 62.5 micrograms once daily.

The adverse reactions identified from the four pivotal studies and the long term safety study (which involved 1,412 patients who received INCRUSE ELLIPTA) are presented in the table below.

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as:

Very common: $\geq 1/10$

Common: $\geq 1/100$ to $< 1/10$

Uncommon: $\geq 1/1000$ to $< 1/100$

Rare: $\geq 1/10000$ to $< 1/1000$

Very rare: $< 1/10000$

<u>MedDRA</u> System organ class	Adverse reaction(s)	Frequency
Infections and infestations	Urinary tract infection	Common
	Sinusitis	Common
	Nasopharyngitis	Common
	Upper Respiratory Tract Infection	Common
Cardiac Disorders	Atrial Fibrillation	Uncommon
	Supraventricular tachycardia	Uncommon
	Tachycardia	Common
Respiratory, Thoracic and Mediastinal Disorders	Cough	Common
Gastrointestinal Disorders	Constipation	Uncommon
	Dry mouth	Uncommon

Post-marketing data

MedDRA System organ class	Adverse reaction(s)	Frequency
Immune system disorders	Hypersensitivity reactions including: Rash, urticaria and pruritus Anaphylaxis, angioedema	Uncommon Rare
Nervous system disorders	Dysgeusia	Common
Eye disorders	Vision blurred Eye Pain Glaucoma	Rare Rare Rare
Respiratory, thoracic and mediastinal disorders	Dysphonia Oropharyngeal pain	Rare Rare
Renal and urinary disorders	Urinary retention Dysuria	Rare Rare

Umeclidinium in combination with ICS/LABA

In addition to the umeclidinium monotherapy adverse reactions reported above, adverse reactions occurring with INCRUSE ELLIPTA in combination with an ICS/LABA (either fluticasone furoate/vilanterol 100 mcg/25 mcg or fluticasone propionate/salmeterol 250 mcg/50 mcg) in four 12-week studies (pooled data), at an incidence of greater than or equal to 1% and exceeding ICS/LABA alone, were oropharyngeal pain, back pain, diarrhoea, headache and dysgeusia. The safety data for long term use is limited given the short duration of the studies.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

No data from clinical studies are available regarding overdose with INCRUSE ELLIPTA.

Symptoms and signs

An overdose of INCRUSE ELLIPTA will likely produce signs and symptoms consistent with the known inhaled muscarinic antagonist adverse effects (e.g. dry mouth, visual accommodation disturbances and tachycardia).

Treatment

If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

For information on the management of overdose, contact the Poison Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Umeclidinium is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic). It is a quinuclidine derivative that is a muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic acetylcholine receptors on airway smooth muscle. It demonstrates slow reversibility at the human M3 muscarinic receptor subtype in vitro and a long duration of action in vivo when administered directly to the lungs in pre-clinical models.

Pharmacodynamic effects

Improvement in lung function over placebo was seen at 15 minutes (the first time point assessed after dosing) and was maintained over 24 hours. There was no evidence for tachyphylaxis to the bronchodilator effect after repeated dosing of Incruse Ellipta 125 micrograms for up to 52 weeks in COPD patients.

In a 24-week, placebo controlled clinical efficacy study in COPD patients, INCRUSE ELLIPTA 62.5 micrograms increased forced expiratory volume in one second (FEV1) after the first dose on Day 1 with an improvement of 0.07 L at 15 minutes compared with placebo ($p < 0.001$). The increase from baseline to peak FEV1 over the first 6 hours post-dose at Day 1 was 0.23 L with umeclidinium 62.5 micrograms compared with 0.11 L for placebo. The increase from baseline to peak FEV1 over the first 6 hours post-dose at Week 24 was 0.23 L with umeclidinium 62.5 micrograms compared with 0.10 L for placebo.

Cardiovascular effects

The effect of umeclidinium 500 micrograms on the QT interval was evaluated in a placebo and moxifloxacin controlled QT study of 103 healthy volunteers. Following repeat doses of 500 micrograms once daily for 10 days, no clinically relevant effect on prolongation of QT interval (corrected using the Fridericia method) was observed.

Clinical trials

Placebo controlled studies

The efficacy of INCRUSE ELLIPTA administered once daily was evaluated in two placebo controlled clinical studies, in adult patients with a clinical diagnosis of COPD; a 12-week study (AC4115408) and a 24 week study (DB2113373). In the 12-week study, INCRUSE

ELLIPTA demonstrated statistically significant and clinically meaningful improvements in measures of lung function (as defined by change from baseline trough FEV₁ at Week 12, which was the primary efficacy endpoint compared with placebo (see *Table 2*). The bronchodilatory effects with INCRUSE ELLIPTA compared with placebo were evident after the first day of treatment and were maintained over the 12-week treatment period.

Table 2. Primary efficacy endpoint at Week 12 (Study AC4115408)

	Trough FEV ₁ (L)		
			Difference from Placebo
	Baseline (SD)	Change from baseline (SE)	Treatment Difference (95% CI) p-value
Study AC4115408			
INCRUSE ELLIPTA 62.5 micrograms OD (n= 69)	1.26 (0.57)	0.12 (0.03)	0.13 (0.05,0.20) <0.001
Placebo (n=68)	1.21 (0.43)	-0.01 (0.03)	-

Abbreviations: CI= confidence interval; FEV₁= forced expiratory volume in 1 second; L= litres; n= number randomized to treatment; OD= once daily; SD= standard deviation; SE= standard error.

INCRUSE ELLIPTA demonstrated a statistically significant greater improvement from baseline in weighted mean FEV₁ over 0-6 hours post-dose at Week 12 compared with placebo (0.17 L (p<0.001)).

The percentage of patients receiving INCRUSE ELLIPTA that responded with a minimum clinically important difference (MCID) of ≥1 unit Transition Dyspnoea Index (TDI) focal score at Week 12 was 38% (24/64) compared with 15% (8/53) for placebo. The odds of being a TDI responder vs. a non responder, was statistically significantly greater for INCRUSE ELLIPTA compared with placebo at Week 12 (Odds Ratio 3.4 (95% CI 1.3,8.4), p=0.009).

INCRUSE ELLIPTA demonstrated statistically significant improvements from placebo in the change from baseline in total score at Week 12 for the St. George's Respiratory Questionnaire (SGRQ), a disease-specific health status measure (-7.90 units) (p<0.001). The percentage of patients receiving INCRUSE ELLIPTA that responded with a reduction of ≥4 units (MCID) in SGRQ total score at Week 12 was 44% (28/63) compared with 26% (14/54) for placebo. The odds of being a SGRQ responder vs. a non responder, was statistically significantly greater for INCRUSE ELLIPTA compared with placebo at Week 12 (Odds Ratio 2.44 (95% CI 1.08, 5.50), p=0.032).

In addition, patients treated with INCRUSE ELLIPTA required less rescue salbutamol over the 12-week treatment period than those treated with placebo (mean reduction of 0.7 puffs per day and the difference from placebo was statistically significant (p=0.025)).

In the 24-week study, DB2113373, INCRUSE ELLIPTA demonstrated statistically significant improvements in lung function (as defined by change from baseline trough FEV₁ at Week 24, which was the primary efficacy endpoint compared with placebo (see *Table 3*). The bronchodilatory effects with INCRUSE ELLIPTA compared with placebo were evident after the first day of treatment and were maintained over the 24-week treatment period.

Table 3. Primary efficacy endpoint at Week 24 (Study DB2113373)

	Trough FEV ₁ (L)		
			Difference from Placebo
	Baseline (SD)	Change from baseline (SE)	Treatment Difference (95% CI) p-value
Study DB2113373			
INCRUSE ELLIPTA 62.5 micrograms OD (n= 418)	1.20 (0.49)	0.12 (0.01)	0.12 (0.08,0.16) <0.001
Placebo (n=280)	1.20 (0.47)	0.00 (0.02)	-

Abbreviations: CI= confidence interval; FEV₁= forced expiratory volume in 1 second; L= litres; n= number randomized to treatment; OD= once daily; SD= standard deviation; SE= standard error.

INCRUSE ELLIPTA demonstrated a statistically significant greater improvement from baseline in weighted mean FEV₁ over 0-6 hours post-dose at Week 24 compared with placebo (0.15L; p<0.001).

A statistically significant improvement from placebo in the TDI focal score at Week 24 was demonstrated for INCRUSE ELLIPTA (1.0 units) (p<0.001). The percentage of patients receiving INCRUSE ELLIPTA that responded with a minimum clinically important difference (MCID) of ≥1 unit TDI focal score at Week 24 was 53% (207/394) compared with 41% (106/260) for placebo. The odds of being a TDI responder vs. a non responder, was statistically significantly greater for INCRUSE ELLIPTA compared with placebo at Week 24 (Odds Ratio 1.6 (95% CI 1.2, 2.3), p=0.002).

A statistically significant improvement from placebo in the change from baseline in total score at Week 24 for the St. George's Respiratory Questionnaire (SGRQ), a disease-specific health status measure, was also demonstrated for INCRUSE ELLIPTA (-4.69 units) (p≤0.001). The percentage of patients receiving INCRUSE ELLIPTA that responded with a reduction of ≥4 units (MCID) in SGRQ total score at Week 24 was 44% (172/388) compared with 34% (86/254) for placebo. The odds of being a SGRQ responder vs. a non responder, was statistically significantly greater for INCRUSE ELLIPTA compared with placebo at Week 24 (Odds Ratio 1.6 (95% CI 1.2,2.3), p=0.003).

Treatment with INCRUSE ELLIPTA lowered the risk of a COPD exacerbation compared with placebo (analysis of time to first exacerbation; Hazard Ratio 0.6, p=0.035, risk reduction 40%).

Supporting efficacy studies

In two 12-week, placebo controlled studies (200109 and 200110), the addition of umeclidinium to fluticasone furoate/vilanterol (FF/VI) (100/25 micrograms) once daily in adult patients with a clinical diagnosis of COPD, resulted in statistically significant improvements in the primary endpoint of trough FEV₁ at Day 85 compared to placebo plus FF/VI (124 mL (95%CI 93, 154, p<0.001) and 122 mL (95%CI 91, 152, p<0.001)).

Improvements in SGRQ at week 12 were not statistically significant (200109) or clinically relevant (200109 and 200110).

The population studied in these trials included patients with moderate to very severe COPD. Subjects were required to have a pre and post salbutamol FEV₁/ forced vital capacity (FVC) ratio of <0.70 and a pre and post salbutamol FEV₁ of <70% of predicted normal values. All subjects had a modified Medical Research Council dyspnoea scale score ≥2.

In study 200109 no patients were GOLD stage 1, 40% were GOLD stage 2, 46% were GOLD stage 3, and 14% GOLD stage 4.

In study 200110, no patients were GOLD stage 1, 48% were GOLD stage 2, 41% were GOLD stage 3 and 11% were GOLD stage 4.

In two 12-week, placebo controlled studies (AC4116135 and AC4116136), the addition of umeclidinium to fluticasone propionate/salmeterol (FSC) (250/50 micrograms) twice daily in adult patients with a clinical diagnosis of COPD, resulted in statistically significant improvements in the primary endpoint of trough FEV₁ at Day 85 compared to placebo plus FSC (147 mL (95%CI 107, 187, p<0.001) and 127 mL (95%CI 89, 164, p<0.001)).

Improvements in SGRQ at week 12 were not statistically significant or clinically relevant for both studies (AC4116135 and AC4116136).

The population studied in these trials included patients with moderate to very severe COPD. Subjects were required to have a pre and post salbutamol FEV₁/ forced vital capacity (FVC) ratio of <0.70 and a pre and post salbutamol FEV₁ of <70% of predicted normal values. All subjects had a modified Medical Research Council dyspnoea scale score ≥2.

In study AC4116135, no patients were GOLD stage 1, 46% were GOLD stage 2, 44% were GOLD stage 3 and 11% were GOLD stage 4.

In study AC4116136 no patients were GOLD stage 1, 40% were GOLD stage 2, 48% were GOLD stage 3, and 12% GOLD stage 4.

The short duration of these four studies and limited number of exacerbation events, preclude any conclusion regarding additional effect of INCRUSE on COPD exacerbation rate.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Following inhaled administration of umeclidinium in healthy volunteers, C_{max} occurred at 5 to 15 minutes. The absolute bioavailability of inhaled umeclidinium was on average 13% of the dose, with negligible contribution from oral absorption. Following repeat dosing of inhaled

umeclidinium, steady state was achieved within 7 to 10 days with 1.5 to 2-fold accumulation. Umeclidinium systemic exposure following inhaled administration was dose proportional.

Distribution

Following intravenous administration to healthy subjects, the mean volume of distribution was 86 litres. *In vitro* plasma protein binding in human plasma was on average 89%.

Metabolism

In vitro studies showed that umeclidinium is metabolised principally by the enzyme P450 CYP2D6 and is a substrate for the P-glycoprotein (P-gp) transporter. The primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (glucuronidation, etc), resulting in a range of metabolites with either reduced pharmacological activity or for which the pharmacological activity has not been established. Systemic exposure to the metabolites is low.

Excretion

Plasma clearance following intravenous administration was 151 litres/hour. Following intravenous administration, approximately 58% of the administered radiolabelled dose (or 73% of the recovered radioactivity) was excreted in faeces by 192 hours post-dose. Urinary elimination accounted for 22% of the administered radiolabelled dose by 168 hours (27% of recovered radioactivity). The excretion of the drug-related material in the faeces following intravenous dosing indicated secretion into the bile. Following oral administration to healthy male subjects, total radioactivity was excreted primarily in faeces (92% of the administered radiolabelled dose or 99% of the recovered radioactivity) by 168 hours post-dose. Less than 1% of the orally administered dose (1% of recovered radioactivity) was excreted in urine, suggesting negligible absorption following oral administration. Umeclidinium plasma elimination half-life following inhaled dosing for 10 days averaged 19 hours, with 3% to 4% drug excreted unchanged in urine at steady-state.

Special patient populations

Elderly

A population pharmacokinetic analysis showed that pharmacokinetics of umeclidinium are similar between COPD patients 65 years and older and those younger than 65 years of age.

Renal impairment

Subjects with severe renal impairment (creatinine clearance <30 mL/min) showed no evidence of an increase in systemic exposure to umeclidinium (C_{max} and AUC), and no evidence of altered protein binding between subjects with severe renal impairment and healthy volunteers.

Hepatic impairment

Subjects with moderate hepatic impairment showed no evidence of an increase in systemic exposure to umeclidinium (C_{max} and AUC), and no evidence of altered protein binding between subjects with moderate hepatic impairment and healthy volunteers. INCRUSE ELLIPTA has not been evaluated in subjects with severe hepatic impairment.

Other patient characteristics

A population pharmacokinetic analysis showed that no dose adjustment is required for umeclidinium based on the effect of age, race, gender, inhaled corticosteroid use, or weight. A study in CYP2D6 poor metabolisers showed no evidence of a clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Umeclidinium was not genotoxic in a standard battery of studies, comprising bacterial mutation assays, the mouse lymphoma tk assay and the rat bone marrow micronucleus test.

Carcinogenicity

Umeclidinium was not carcinogenic in 2-year inhalation studies in mice or rats at doses yielding systemic exposure levels (plasma AUC) up to 26 or 22 times the human clinical exposure of umeclidinium at the maximum recommended dose of 62.5 micrograms per day in the respective species.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

INCRUSE ELLIPTA contains the excipients lactose monohydrate (which contains milk protein) and magnesium stearate.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

If stored in the refrigerator, allow the inhaler to return to room temperature for at least 1 hour before use.

Following removal from the tray, the product may be stored for a maximum period of 6 weeks.

Write the date the inhaler should be discarded on the label in the space provided. The date should be added as soon as the inhaler has been removed from the tray.

6.5 NATURE AND CONTENTS OF CONTAINER

INCRUSE ELLIPTA is a moulded plastic inhaler with a light grey body, a light green mouthpiece cover and a dose counter, packed in a foil tray which contains a desiccant sachet. The tray is sealed with a peelable foil lid. The inhaler contains an aluminium foil laminate strip of either 30 or 7 regularly distributed blisters, each containing a white powder.

Not all pack sizes may be distributed in Australia.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical Name


The chemical name of umeclidinium bromide is 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1).

Chemical Formula

Umeclidinium bromide: $C_{29}H_{34}BrNO_2$

Chemical structure

Umeclidinium bromide:



CAS number

Umeclidinium bromide: 869113-09-7

7 MEDICINE SCHEDULE (POISONS STANDARD)

Schedule 4 – Prescription Only Medicine

8 SPONSOR

GlaxoSmithKline Australia Pty Ltd
Level 4, 436 Johnston Street,
Abbotsford, Victoria, 3067

Phone: 1800 033 109

www.gsk.com.au

9 DATE OF FIRST APPROVAL

8 July 2014

10 DATE OF REVISION

16 June 2023

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.8	Addition of new ADRs information in post marketing data
All sections	Minor editorial and formatting changes

Version 9.0

Trade marks are owned by or licensed to the GSK group of companies.

© 2023 GSK group of companies or its licensor.


How to Use INCRUSE ELLIPTA

What is the Ellipta inhaler?


INCRUSE ELLIPTA is inhaled through the mouth using the Ellipta inhaler.

When you first use the Ellipta inhaler you do not need to check that it is working properly, and you do not need to prepare it for use in any special way. Just follow these step-by-step instructions.

Your Ellipta inhaler carton contains:



The inhaler is packaged in a tray. **Do not open the tray until you are ready to inhale a dose of your medicine.** When you are ready to use your inhaler, peel back the lid to open the tray. The tray contains a **desiccant** sachet, to reduce moisture. Throw this desiccant sachet away - **do not open, eat or inhale it.**



When you take the inhaler out of the sealed tray, it will be in the 'closed' position. **Do not open the inhaler until you are ready to inhale a dose of medicine.** Write the "Discard by" date on the inhaler label in the space provided. The "Discard by" date is 6 weeks from the date you open the tray. **After this date, the inhaler should no longer be used.**


The step-by-step instructions shown below for the 30-dose (30 day supply) Ellipta inhaler also apply to the 7-dose (7 day supply) Ellipta inhaler.

Important information to read before you start

If you open and close the cover without inhaling the medicine, you will lose the dose.

The lost dose will be securely held inside the inhaler, but it will no longer be available.


It is not possible to accidentally take extra medicine or a double dose in one inhalation.



Step 1: Prepare a dose

Wait to open the cover until you are ready to take your dose. Do not shake the inhaler.

- Slide the cover fully down until you hear a "click".



Your medicine is now ready to be inhaled.


The dose counter counts down by 1 to confirm.

If the dose counter does not count down as you hear the “click”, the inhaler will not deliver medicine. Take it back to your pharmacist for advice.

Do not shake the inhaler at any time.

Step 2: Inhale your medicine

- **Whilst holding the inhaler away from your mouth, breathe out as far as is comfortable.**
- **Do not** breathe out into the inhaler.
- **Put the mouthpiece between your lips, and close your lips firmly around it. Do not** block the air vent with your fingers.



- Take one long, steady, deep breath in. Hold this breath for about 3-4 seconds or for as long as is comfortable.

- Remove the inhaler from your mouth.
- Breathe out slowly and gently away from the mouthpiece.

You may not be able to taste or feel the medicine, even when you are using the inhaler correctly.

If you want to clean the mouthpiece, use a **dry tissue, before** you close the cover.

Step 3: Close the inhaler

- Slide the cover upwards as far as it will go, to cover the mouthpiece.